Clinical trials
Arterial Hypertension clinical trials
Below are recruiting arterial hypertension clinical trials, each written for real people, not researchers. We’re tracking 169 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04160533Recruiting
Registry for people diagnosed with high blood pressure
This registry collects information from people who have been diagnosed with high blood pressure. It may help researchers better understand who has it and how it’s managed in real life.
Moscow, Moscow OblastAges 18–99 - NCT04555161Recruiting
Test of an implanted device for pulmonary arterial hypertension
This trial studies an implanted system (the Aria CV Pulmonary Hypertension System) to treat pulmonary arterial hypertension, a serious lung-blood vessel and heart condition. It aims to see whether the device can improve outcomes for people who are still sick despite existing PH medicines.
La Jolla, CaliforniaAges 18 years+ - NCT05462574Recruiting
MRI study of heart fat in pulmonary arterial hypertension
This trial uses MRI (and an additional MRI measurement called MRS) to study fat in the right side of the heart in people with pulmonary arterial hypertension (PAH). It may help researchers understand what’s going on in PAH and how it relates to symptoms and exercise ability.
Nashville, TennesseeAges 18 years+ - NCT05584722Recruiting
Study risk and resilience in pulmonary arterial hypertension
This study looks at how people with pulmonary arterial hypertension (PAH) and certain genetic risks cope and how their bodies respond over time. It may help researchers understand factors linked to better or worse outcomes, and how different people manage the condition.
Nashville, TennesseeAges 15–80 - NCT06098300Recruiting
How blood pressure changes affect eye blood vessels
This trial is studying how changes in blood pressure affect the tiny blood vessels in the back of the eye (retina). It may help people with high blood pressure understand how treatment impacts their eye health.
ViennaAges 18–90 - NCT06104228RecruitingPhase 2
Xenon MRI to detect and track pulmonary hypertension
This trial uses a special MRI scan (using xenon gas) to see how well the lungs are working in people with pulmonary arterial hypertension (PAH). It aims to improve diagnosis and monitoring of PAH from connective tissue disease or unknown cause.
Durham, North CarolinaAges 18–75 - NCT06454838Recruiting
Exercise and blood vessel health in children with pulmonary hypertension
This study looks at how exercise affects the lungs, blood vessels, and oxygen use in children with pulmonary arterial hypertension (high blood pressure in the lungs). It compares them to healthy children to understand how the condition impacts the body.
Ankara, ÇankayaAges 6–18 - NCT06554301RecruitingPhase 1
Empagliflozin for pulmonary arterial hypertension study
This study tests if the diabetes drug empagliflozin can help people with pulmonary arterial hypertension (PAH), a condition causing high blood pressure in the lungs. It aims to see if the drug improves symptoms and is safe for patients with moderate symptoms.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06658522RecruitingPhase 4
Sotatercept for right heart function in pulmonary hypertension
This study tests a medicine called sotatercept to see if it can improve how the right side of your heart pumps in people with PAH. It may help you feel better and slow down the disease.
Amsterdam, North HollandAges 18–70 - NCT07013149Recruiting
Switching PAH medicines: does it change your risk?
This study looks at how changing from one PAH medicine (ambrisentan) to another (bosentan) affects your disease risk over time. It compares people who made the switch to those who stayed on ambrisentan.
São Paulo, São PauloAges 18 years+ - NCT06850792Recruiting
Improving treatment adherence with telemedicine and guidance
This study tests whether regular remote check-ins and guidance can help people with pulmonary arterial hypertension stick to their treatment plan. You would be followed by phone or video from University of Sao Paulo.
São Paulo, São PauloAges 18 years+ - NCT06998329Recruiting
PAH diagnosis timing study
This study looks at the timing between first symptoms and diagnosis of pulmonary arterial hypertension (PAH). It aims to better understand how quickly patients get diagnosed after symptoms appear.
São Paulo, São PauloAges 18 years+ - NCT07120789Recruiting
Understanding pulmonary hypertension knowledge questionnaire
This study aims to validate a questionnaire that measures how well patients understand pulmonary hypertension. If you have been diagnosed with Group 1 Pulmonary Arterial Hypertension (PAH) and can read the questionnaire, you may be able to help researchers make sure it's a useful tool.
São Paulo, São PauloAges 18 years+ - NCT07217522Recruiting
Genetics of pulmonary hypertension study
This study looks at the genes that may be linked to pulmonary hypertension. By providing a saliva sample and filling out a health survey from home, you can help researchers learn more about this condition.
Piscataway, New JerseyAges 18 years+ - NCT01884051Recruiting
Study of blood and skin changes in pulmonary hypertension
This study looks at how hormones, metabolism, and body signals relate to pulmonary arterial hypertension. You may be eligible if you (or a family member) have idiopathic, inherited, or related pulmonary arterial hypertension, and you can do required blood and other testing.
Nashville, TennesseeAges Up to 90 years - NCT06804122Recruiting
Exercise rehab for pulmonary arterial hypertension
This trial tests a supervised exercise program for people with pulmonary arterial hypertension (PAH), a type of high blood pressure in the lungs. It aims to see if regular exercise can improve your daily function and quality of life.
Tampere, PirkanmaaAges 18 years+ - NCT06992440RecruitingPhase 2
Empagliflozin for better right heart function in pulmonary hypertension
This trial tests if a diabetes drug can help people with pulmonary arterial hypertension whose right heart function is reduced. Participants take empagliflozin or a placebo for 24 weeks to see if heart function improves.
Baltimore, MarylandAges 18 years+ - NCT07713914RecruitingPhase 4
Triple therapy vs sildenafil dose increase for PAH
This study compares two approaches for people with PAH whose current treatment (a combination of sildenafil and an endothelin receptor antagonist) needs to be stepped up. Half the participants will add a third medicine (iloprost or selexipag), while the other half will increase their sildenafil dose. The goal is to see which strategy works better for improving symptoms and lowering risk.
São Paulo, São PauloAges 18 years+ - NCT06680986Recruiting
AI heart ultrasound study for high blood pressure
This trial uses artificial intelligence to analyze heart ultrasound images from people who had high blood pressure evaluations during a hospital stay. It aims to better understand how high blood pressure affects the heart.
Pierre-BéniteAges 18 years+ - NCT06872112RecruitingPhase 1
Artesunate for pulmonary arterial hypertension safety study
This trial tests if artesunate, a malaria drug, is safe and tolerable for people with pulmonary arterial hypertension (PAH). It may offer a new treatment option for PAH patients whose symptoms persist despite using two or more standard therapies.
Stanford, CaliforniaAges 18–60 - NCT07140484RecruitingPhase 4
Sotatercept for pulmonary arterial hypertension
This study tests a new medication called sotatercept for people with pulmonary arterial hypertension (PAH) who are already on at least two other PAH treatments. The goal is to see if adding sotatercept can improve symptoms and exercise ability.
Edmonton, AlbertaAges 18 years+ - NCT07366879Recruiting
Exercise program for newly diagnosed pulmonary hypertension
This study tests whether a home-based exercise program, added to your regular medications, can help people who are newly diagnosed with pulmonary arterial hypertension feel better and improve their daily function.
GlasgowAges 18 years+ - NCT01712620RecruitingPhase 2
Spironolactone for pulmonary arterial hypertension in stable patients
This trial studies whether spironolactone can improve pulmonary arterial hypertension, a disease that makes the blood vessels in the lungs work too hard. You may be eligible if your condition is confirmed by specific heart-lung pressure tests and your medication plan has been stable for at least 4 weeks.
Bethesda, MarylandAges 18–100 - NCT07457762Recruiting
Reminder app for pulmonary hypertension inhaler
This study tests if a smartphone app can help people with pulmonary arterial hypertension (PAH) stick to their inhaled iloprost treatment. It is for adults already on this treatment at a specific clinic in Brazil.
São Paulo, São PauloAges 18 years+
Hear when a new Arterial Hypertension trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for arterial hypertension?
- Yes. Clin2 currently lists 169 recruiting arterial hypertension studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a arterial hypertension trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a arterial hypertension trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.